投资银行Piper Sandler近日发布研究报告,首次覆盖康乃德生物医药,并给予其股票“增持”评级,同时设定7美元的目标价。
投资银行Piper Sandler近日发布研究报告,首次覆盖康乃德生物医药,并给予其股票“增持”评级,同时设定7美元的目标价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.